A majority of immune checkpoint-associated genes are co-expressed with TARS1, implying that it may be inter-regulated with multiple targets in the immune checkpoint-associated pathway and could be a predictive biomarker of efficacy or a novel therapeutic target for ICI in the treatment of BC. The gene discussed is TARS1; the disease is breast cancer.